Literature DB >> 14639661

Corticobasal degeneration as a cognitive disorder.

Naida L Graham1, Thomas H Bak, John R Hodges.   

Abstract

The presence of cognitive impairment in corticobasal degeneration (CBD) is now widely recognised. Our review of the literature reveals that, although the pattern and severity of neuropsychological impairments can be highly variable across patients, several general trends can be identified. The most characteristic impairments are limb apraxia (usually ideomotor), constructional and visuospatial difficulties, acalculia, frontal dysfunction, and nonfluent aphasia. The limb apraxia is associated with deficits in drawing, copying, and handwriting, but there is emerging evidence that the problems with handwriting are not due exclusively to the apraxia. The findings with respect to episodic memory are more variable, but when there is impairment in this area, it tends to be milder than that seen in Alzheimer's disease. Semantic memory functioning appears relatively preserved but has been poorly studied. Problems with speech are common, and may be due to dysarthria or buccofacial apraxia. Aphasia, although initially considered rare, is in fact a common accompaniment of CBD, may be the presenting feature, and is typically nonfluent in type. More systematic investigation of the clinical and neuropathological overlap between progressive nonfluent aphasia (generally considered to be a form of frontotemporal dementia) and CBD is needed.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14639661     DOI: 10.1002/mds.10536

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  27 in total

1.  Some is not enough: quantifier comprehension in corticobasal syndrome and behavioral variant frontotemporal dementia.

Authors:  Brianna Morgan; Rachel G Gross; Robin Clark; Michael Dreyfuss; Ashley Boller; Emily Camp; Tsao-Wei Liang; Brian Avants; Corey T McMillan; Murray Grossman
Journal:  Neuropsychologia       Date:  2011-09-12       Impact factor: 3.139

2.  Creutzfeldt-Jakob disease mimicking corticobasal degeneration clinical and MRI data of a case.

Authors:  O Moreaud; A Monavon; M P Brutti-Mairesse; S Grand; J F Lebas
Journal:  J Neurol       Date:  2005-04-04       Impact factor: 4.849

Review 3.  Hashimoto's encephalopathy : epidemiology, pathogenesis and management.

Authors:  Ramon Mocellin; Mark Walterfang; Dennis Velakoulis
Journal:  CNS Drugs       Date:  2007       Impact factor: 5.749

4.  Behavioral variant frontotemporal dementia with corticobasal degeneration pathology: phenotypic comparison to bvFTD with Pick's disease.

Authors:  Katherine P Rankin; Mary Catherine Mayo; William W Seeley; Suzee Lee; Gil Rabinovici; Maria Luisa Gorno-Tempini; Adam L Boxer; Michael W Weiner; John Q Trojanowski; Stephen J DeArmond; Bruce L Miller
Journal:  J Mol Neurosci       Date:  2011-09-01       Impact factor: 3.444

Review 5.  Recognizing Atypical Parkinsonisms: "Red Flags" and Therapeutic Approaches.

Authors:  Nikolaus R McFarland; Christopher W Hess
Journal:  Semin Neurol       Date:  2017-05-16       Impact factor: 3.420

Review 6.  Diagnostic Approach to Atypical Parkinsonian Syndromes.

Authors:  Nikolaus R McFarland
Journal:  Continuum (Minneap Minn)       Date:  2016-08

Review 7.  Psychiatric issues in cognitive impairment.

Authors:  Dag Aarsland; John-Paul Taylor; Daniel Weintraub
Journal:  Mov Disord       Date:  2014-04-15       Impact factor: 10.338

8.  Complex Neurological Phenotype in Female Carriers of NHE6 Mutations.

Authors:  Matthew F Pescosolido; Brian C Kavanaugh; Nathalie Pochet; Michael Schmidt; Beth A Jerskey; Jeffrey M Rogg; Philip L De Jager; Tracy L Young-Pearse; Judy S Liu; Eric M Morrow
Journal:  Mol Neuropsychiatry       Date:  2019-03-06

Review 9.  A model-based approach to understanding apraxia in Corticobasal Syndrome.

Authors:  Vessela Stamenova; Eric A Roy; Sandra E Black
Journal:  Neuropsychol Rev       Date:  2008-12-11       Impact factor: 7.444

10.  Apraxia in progressive nonfluent aphasia.

Authors:  Jonathan Daniel Rohrer; Martin N Rossor; Jason D Warren
Journal:  J Neurol       Date:  2009-11-12       Impact factor: 4.849

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.